ACE and hydrops fetalis: Data from the US CHAMP-HF registry show that a minority of patients with HF receive stable target doses of RAASis over 12 months of follow-up; in fact, 73.0% of patients receiving angiotensin-converting enzyme inhibitors (ACEis) or angiotensin II receptor blockers (ARBs) had stable sub-target doses over this time, and 11.5% had a dose reduction or discontinued the ACEi/ARB [40].